Project on the Decade of the Brain. www.loc.gov/loc/brain/ [accessed 2014 Nov 20].
Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatment (CANMAT). Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001; 46 Suppl1: 1S-92S.
Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004; 18 (13): 911-32.
Goodwin GM. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 1996; 57(S4):9–13.
Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003; 17 (5): 343-62.
Forest Laboratories Inc. Lexapro™ (escitalopram oxalate) US prescribing information [online]. Available from URL: http://www.fda.gov [Accessed 2014 Nov19]
H.Lundbeck AS. Cipralex: European summary of product characteristics [online]. Available from URL: http://www.cipralex.com/images/Cipralex/smpc.pdf [Accessed 2014 Nov 21]
Lundbeck Canada Inc. Annotated prescribing information: escitalopram. Canada: Lundbeck Canada Inc., 2005.
Chen F, Larsen MB, Sanchez C. The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005 Mar; 15 (2): 193-8.
Baldessarini RJ. Drugs and the treatment of psychiatric disorders, depression, and anxiety disorders. In: Hardman JG, Limbird LE, editors. Goodman and Gillman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2001:437.
Thase ME, Entsuah AR, Rudolph RL. Remisssion rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241.
Tran PV, Bymaster FP, McNamara RK, Potter WZ. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003; 23(1):78-86.
Nelson JC. Synergistic benefits of serotonin and noradrenaline reuptake inhibition. Depress Anxiety 1998; 7(suppl 1):5-6.
American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157(suppl 4):1-45.
Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ, Wiltse C, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002; 63:225–31.
Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63:308–15.
Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatric Res 2002; 36:383–90.
Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005 May; 20 (3): 131-7.
Alexopoulos GS, Gordon J, Zhang D. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder [abstract no. 54]. Neuropsychopharmacology 2004; 29 Suppl. 1: 87.
Baldwin D, Hindmarch I, Huusom AKT. Escitalopram and paroxetine in the short and long-term treatment of major depressive disorder (MDD) [abstract no. P01.135]. Int J Neuropsychopharmacol 2004 Jun 22; 7 Suppl. 1: S168.
Wightman D, Horrigan JP, Modell JG. The tolerability and safety of bupropion XL versus escitalopram in the treatment of major depressive disorder [poster]. 13th Congress of the Association of European Psychiatrists (AEP); 2005 Apr 2-6; Munich.
Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004 Sep; 65 (9): 1190-6.
Metrics powered by PLOS ALM
- There are currently no refbacks.
Copyright (c) 2015 International Journal of Pharmacological Research
This work is licensed under a Creative Commons Attribution 4.0 International License.